| Literature DB >> 33949283 |
Euphemia Sibanda1, Ania Shapiro2, Bradley Mathers2, Annette Verster3, Rachel Baggaley4, Mary E Gaffield5, Virginia Macdonald3.
Abstract
There is limited information on contraceptive values and preferences of sex workers. We conducted a mixed-method study to explore contraceptive values and preferences among sex workers. We conducted an online survey with individuals from 38 countries (n = 239), 6 focus group discussions (FGD, n = 68) in Zimbabwe, and 12 in-depth phone interviews (IDI) across 4 world regions, in June and July of 2019. Participants were asked about awareness of contraceptives, methods they had used in the past, and the determinants of their choices. Differences between respondents from high-, low- and middle- income countries were examined. Qualitative data were analysed thematically. Survey participants reported an awareness of modern contraceptive methods. FGDs found that younger women had lower awareness. Reports of condomless sex were common and modern contraceptive use was inconsistent. Determinants of contraceptive choices differed by setting according to results of the survey, FGD, and IDI. Regardless of country income level, determinants of contraceptive choices included ease of use, ease of access to a contraceptive method, and fewer side effects. Healthcare provider attitudes, availability of methods, and clinic schedules were important considerations. Most sex workers are aware of contraceptives, but barriers include male partners/clients, side effects, and health system factors such as access and clinic attitudes towards sex workers.Entities:
Keywords: HIV; contraception; family planning; focus group discussion; sex workers; survey; values and preferences
Year: 2021 PMID: 33949283 PMCID: PMC8118510 DOI: 10.1080/26410397.2021.1913787
Source DB: PubMed Journal: Sex Reprod Health Matters ISSN: 2641-0397
Online survey respondents characteristics
| Characteristic | High-income countries | Low- and middle-income countries | Total | |
|---|---|---|---|---|
| 32.1 | 33.0 | 32.6 | 0.372 | |
| 18–25 | 27 (20.9%) | 25 (23.4%) | 52 (21.8%) | 0.495 |
| 26–30 | 36 (27.9%) | 20 (18.7%) | 57 (23.8%) | |
| 31–35 | 26 (20.2%) | 19 (17.8%) | 46 (19.2%) | |
| 36–40 | 22 (17.1%) | 18 (16.8%) | 41 (17.2%) | |
| >40 | 18 (14.0%) | 25 (23.4%) | 43 (18.0%) | |
| 0.3 | 1.2 | 0.7 | <0.001 | |
| 0 | 104 (80.6%) | 39 (36.8%) | 143 (60.6%) | <0.001 |
| 1 | 12 (9.3%) | 33 (31.1%) | 45 (19.1%) | |
| 2 | 13 (10.1%) | 34 (32.1%) | 48 (20.3%) | |
Includes three respondents not reporting country of residence and omitted from analysis of country income categories.
Information on, knowledge about, access to and use of contraceptive methods, results of online survey
| Low- and middle-income countries ( | High-income countries ( | High- vs low- and middle-income countries | Total ( | ||
|---|---|---|---|---|---|
| At work | 37 (34.6%) | 22 (17.1%) | 0.002 | 59 (24.7%) | |
| Drop-in centre | 12 (11.2%) | 40 (31.0%) | <0.001 | 52 (21.8%) | |
| Friends or family | 33 (30.8%) | 58 (45.0%) | 0.027 | 91 (38.1%) | |
| Healthcare providers | 61 (57.0%) | 98 (76.0%) | 0.002 | 162 (67.8%) | |
| Mobile clinic | 17 (15.9%) | 6 (4.7%) | 0.004 | 23 (9.6%) | |
| NGO or CBO | 44 (41.1%) | 43 (33.3%) | 0.217 | 87 (36.4%) | |
| Outreach worker | 25 (23.4%) | 13 (10.1%) | 0.006 | 38 (15.9%) | |
| Internet | 56 (52.3%) | 93 (72.1%) | 0.002 | 151 (63.2%) | |
| Don’t access | 2 (1.9%) | 4 (3.1%) | 0.692 | 6 (2.5%) | |
| At or through work | 19 (17.8%) | 19 (14.7%) | 0.52 | 39 (16.3%) | |
| Pharmacy | 67 (62.6%) | 70 (54.3%) | 0.195 | 138 (57.7%) | |
| Drop-in centre | 9 (8.4%) | 35 (27.1%) | 0.000 | 45 (18.8%) | |
| Family planning clinic | 28 (26.2%) | 39 (30.2%) | 0.491 | 68 (28.5%) | |
| Friends or family | 6 (5.6%) | 10 (7.8%) | 0.798 | 17 (7.1%) | |
| Mobile clinics | 19 (17.8%) | 7 (5.4%) | 0.003 | 26 (10.9%) | |
| NGO/CBO | 34 (31.8%) | 33 (25.6%) | 0.015 | 68 (28.5%) | |
| Outreach workers | 16 (15.0%) | 11 (8.5%) | 0.123 | 27 (11.3%) | |
| Private clinic or hospital | 23 (21.5%) | 21 (16.3%) | 0.306 | 45 (18.8%) | |
| Public clinic or hospital | 26 (24.3%) | 48 (37.2%) | 0.033 | 75 (31.4%) | |
| Other | 4 (3.7%) | 33 (25.6%) | – | 38 (15.9%) | |
| Male condoms | 105 (98.1%) | 127 (98.4%) | 1.000 | 235 (98.3%) | |
| Female condoms | 92 (86.0%) | 122 (94.6%) | 0.024 | 216 (90.4%) | |
| Diaphragm | 27 (25.2%) | 113 (87.6%) | <0.001 | 142 (59.4%) | |
| Non-hormonal (copper) IUDs | 73 (68.2%) | 121 (93.8%) | <0.001 | 196 (82.0%) | |
| Tubal ligation | 78 (72.9%) | 123 (95.3%) | <0.001 | 203 (84.9%) | |
| Vasectomy | 67 (62.6%) | 124 (96.1%) | <0.001 | 193 (80.8%) | |
| Traditional methods | 63 (58.9%) | 118 (91.5%) | <0.001 | 183 (76.6%) | |
| Oral pill | 94 (87.9%) | 125 (96.9%) | 0.007 | 221 (92.5%) | |
| Contraceptive rings | 38 (35.5%) | 108 (83.7%) | <0.001 | 146 (61.1%) | |
| Hormonal contraceptive patches | 34 (31.8%) | 98 (76.0%) | <0.001 | 133 (55.6%) | |
| Hormonal IUDs | 53 (49.5%) | 111 (86.0%) | <0.001 | 165 (69.0%) | |
| Injectables | 54 (50.5%) | 101 (78.3%) | <0.001 | 157 (65.7%) | |
| Hormonal implants | 52 (48.6%) | 111 (86.0%) | <0.001 | 165 (69.0%) | |
| Emergency contraceptive | 80 (74.8%) | 124 (96.1%) | <0.001 | 206 (86.2%) | |
| Male condoms | 100 (93.5%) | 122 (94.6%) | 0.718 | 225 (94.1%) | |
| Female condoms | 22 (20.6%) | 34 (26.4%) | 0.297 | 56 (23.4%) | |
| Diaphragm | 1 (0.9%) | 4 (3.1%) | 0.381 | 5 (2.1%) | |
| Non-hormonal (copper) IUDs | 6 (5.6%) | 15 (11.6%) | 0.106 | 21 (8.8%) | |
| Tubal ligation | 5 (4.7%) | 9 (7.0%) | 0.456 | 14 (5.9%) | |
| Vasectomy | 1 (0.9%) | 10 (7.8%) | 0.014 | 11 (4.6%) | |
| Traditional methods | 20 (18.7%) | 23 (17.8%) | 0.864 | 43 (18.0%) | |
| Oral pill | 29 (27.1%) | 26 (20.2%) | 0.209 | 55 (23.0%) | |
| Contraceptive rings | 0 (0.0%) | 5 (3.9%) | 0.065 | 5 (2.1%) | |
| Hormonal contraceptive patches | 1 (0.9%) | 1 (0.8%) | 1.000 | 2 (0.8%) | |
| Hormonal IUDs | 3 (2.8%) | 20 (15.5%) | <0.001 | 23 (9.6%) | |
| Injectables | 13 (12.1%) | 6 (4.7%) | 0.035 | 19 (7.9%) | |
| Hormonal implants | 7 (6.5%) | 10 (7.8%) | 0.720 | 17 (7.1%) | |
| Emergency contraceptive | 22 (20.6%) | 27 (20.9%) | 0.944 | 50 (20.9%) | |
| All the time | 87 (81.3%) | 113 (87.6%) | 0.031 | 203 (84.9%) | |
| More than half the time | 10 (9.3%) | 12 (9.3%) | 22 (9.2%) | ||
| Half the time | 5 (4.7%) | 1 (0.8%) | 6 (2.5%) | ||
| Less than half the time | 2 (1.9%) | 0 (0.0%) | 2 (0.8%) | ||
| Never | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| N/A | 0 (0.0%) | 3 (2.3%) | 3 (1.3%) | ||
| No response | 3 (2.8%) | 0 (0.0%) | 3 (1.3%) | ||
| All the time | 34 (31.8%) | 28 (21.7%) | 0.03 | 63 (26.4%) | |
| More than half the time | 25 (23.4%) | 30 (23.3%) | 56 (23.4%) | ||
| Half the time | 6 (5.6%) | 14 (10.9%) | 20 (8.4%) | ||
| Less than half the time | 14 (13.1%) | 20 (15.5%) | 34 (14.2%) | ||
| Never | 13 (12.1%) | 24 (18.6%) | 37 (15.5%) | ||
| N/A | 5 (4.7%) | 13 (10.1%) | 19 (7.9%) | ||
| No response | 10 (9.3%) | 0 (0.0%) | 10 (4.2%) |
Includes three respondents not reporting country of residence and omitted from analysis of country income categories.
Figure 1.Importance of contraceptive attributes, comparing respondents from high-income countries (HIC) and low- and middle-income countries (LMIC)
Preferred dosing
| Low- and middle-income countries ( | High-income countries ( | TOTAL ( | |||
|---|---|---|---|---|---|
| Take every day | 13 (12.1%) | 5 (3.9%) | 0.007 | 19 (7.9%) | |
| Take every few months | 15 (14.0%) | 9 (7.0%) | 24 (10.0%) | ||
| Take every few weeks | 3 (2.8%) | 2 (1.6%) | 5 (2.1%) | ||
| Use only when having sex | 36 (33.6%) | 35 (27.1%) | 73 (30.5%) | ||
| Lasts forever | 13 (12.1%) | 37 (28.7%) | 50 (20.9%) | ||
| Protects against pregnancy for years | 26 (24.3%) | 40 (31.0%) | 66 (27.6%) | ||
| No response | 1 (0.9%) | 1 (0.8%) | 2 (0.8%) |
Includes 3 respondents not reporting country of residence and omitted from analysis of country income categories.
Perception of risk and importance of pregnancy, HIV and STI prevention
| Low- and middle-income countries ( | High-income countries ( | TOTAL ( | |||
|---|---|---|---|---|---|
| How important: Effective prevention of pregnancy | Extremely | 57 (53.3%) | 102 (79.1%) | 0.000 | 160 (66.9%) |
| Very | 19 (17.8%) | 19 (14.7%) | 40 (16.7%) | ||
| Somewhat | 8 (7.5%) | 3 (2.3%) | 11 (4.6%) | ||
| Not so | 8 (7.5%) | 1 (0.8%) | 9 (3.8%) | ||
| Not at all | 9 (8.4%) | 4 (3.1%) | 13 (5.4%) | ||
| No response | 6 (5.6%) | 0 (0.0%) | 6 (2.5%) | ||
| How important that it protects against HIV and STIs | Extremely | 34 (31.8%) | 97 (75.2%) | 0.000 | 133 (55.6%) |
| Very | 16 (15.0%) | 13 (10.1%) | 30 (12.6%) | ||
| Somewhat | 19 (17.8%) | 11 (8.5%) | 30 (12.6%) | ||
| Not so | 22 (20.6%) | 6 (4.7%) | 28 (11.7%) | ||
| Not at all | 10 (9.3%) | 1 (0.8%) | 11 (4.6%) | ||
| No response | 6 (5.6%) | 1 (0.8%) | 7 (2.9%) | ||
| Perception of own HIV risk | Very high risk | 9 (8.4%) | 5 (3.9%) | 0.002 | 14 (5.9%) |
| High risk | 16 (15.0%) | 5 (3.9%) | 22 (9.2%) | ||
| Moderate risk | 26 (24.3%) | 38 (29.5%) | 66 (27.6%) | ||
| Low risk | 34 (31.8%) | 68 (52.7%) | 102 (42.7%) | ||
| No risk | 16 (15.0%) | 8 (6.2%) | 24 (10.0%) | ||
| No response | 1 (0.9%) | 1 (0.8%) | 2 (0.8%) |
Includes 3 respondents not reporting country of residence and omitted from analysis of country income categories.
Influence of others on contraceptive decision-making
| Low- and middle-income countries ( | High-income countries ( | TOTAL | |||
|---|---|---|---|---|---|
| Very likely | 52 (48.6%) | 35 (27.1%) | 0.010 | 88 (36.8%) | |
| Somewhat likely | 31 (29.0%) | 60 (46.5%) | 93 (38.9%) | ||
| Neither likely nor unlikely | 9 (8.4%) | 13 (10.1%) | 22 (9.2%) | ||
| Somewhat unlikely | 6 (5.6%) | 9 (7.0%) | 15 (6.3%) | ||
| Very unlikely | 4 (3.7%) | 10 (7.8%) | 14 (5.9%) | ||
| N/A | 3 (2.8%) | 2 (1.6%) | 5 (2.1%) | ||
| No response | 2 (1.9%) | 0 (0.0%) | 2 (0.8%) | ||
| Very likely | 15 (14.0%) | 0 (0.0%) | <0.001 | 16 (6.7%) | |
| Somewhat likely | 17 (15.9%) | 12 (9.3%) | 29 (12.1%) | ||
| Neither likely nor unlikely | 9 (8.4%) | 16 (12.4%) | 26 (10.9%) | ||
| Somewhat unlikely | 9 (8.4%) | 13 (10.1%) | 22 (9.2%) | ||
| Very unlikely | 30 (28.0%) | 77 (59.7%) | 108 (45.2%) | ||
| N/A | 13 (12.1%) | 9 (7.0%) | 22 (9.2%) | ||
| No response | 14 (13.1%) | 2 (1.6%) | 16 (6.7%) | ||
| Very likely | 26 (24.3%) | 14 (10.9%) | <0.001 | 41 (17.2%) | |
| Somewhat likely | 28 (26.2%) | 27 (20.9%) | 56 (23.4%) | ||
| Neither likely nor unlikely | 13 (12.1%) | 20 (15.5%) | 33 (13.8%) | ||
| Somewhat unlikely | 7 (6.5%) | 5 (3.9%) | 12 (5.0%) | ||
| Very unlikely | 26 (24.3%) | 14 (10.9%) | 32 (13.4%) | ||
| N/A | 9 (8.4%) | 41 (31.8%) | 51 (21.3%) | ||
| No response | 13 (12.1%) | 1 (0.8%) | 14 (5.9%) | ||
| Very likely | 17 (15.9%) | 6 (4.7%) | <0.001 | 24 (10.0%) | |
| Somewhat likely | 16 (15.0%) | 26 (20.2%) | 43 (18.0%) | ||
| Neither likely nor unlikely | 15 (14.0%) | 25 (19.4%) | 41 (17.2%) | ||
| Somewhat unlikely | 16 (15.0%) | 26 (20.2%) | 28 (11.7%) | ||
| Very unlikely | 20 (18.7%) | 37 (28.7%) | 57 (23.8%) | ||
| N/A | 14 (13.1%) | 19 (14.7%) | 33 (13.8%) | ||
| No response | 13 (12.1%) | 0 (0.0%) | 13 (5.4%) | ||
| Very likely | 24 (22.4%) | 16 (12.4%) | <0.001 | 41 (17.2%) | |
| Somewhat likely | 29 (27.1%) | 51 (39.5%) | 82 (34.3%) | ||
| Neither likely nor unlikely | 12 (11.2%) | 26 (20.2%) | 38 (15.9%) | ||
| Somewhat unlikely | 8 (7.5%) | 13 (10.1%) | 21 (8.8%) | ||
| Very unlikely | 13 (12.1%) | 16 (12.4%) | 29 (12.1%) | ||
| N/A | 7 (6.5%) | 7 (5.4%) | 14 (5.9%) | ||
| No response | 14 (13.1%) | 0 (0.0%) | 14 (5.9%) | ||
Includes 3 respondents not reporting country of residence and omitted from analysis of country income categories.
. Causes of contraceptive switching and/or discontinuation
| Low- and middle-income countries ( | High-income countries ( | TOTAL | |||
|---|---|---|---|---|---|
| Difficulties accessing methods | 41 (38.3%) | 84 (65.1%) | <0.001 | 127 (53.1%) | |
| Disapproval from clients | 28 (26.2%) | 14 (10.9%) | 0.002 | 42 (17.6%) | |
| Disapproval from spouse | 21 (19.6%) | 13 (10.1%) | 0.038 | 34 (14.2%) | |
| Disapproval from other sexual partners | 13 (12.1%) | 9 (7.0%) | 0.174 | 22 (9.2%) | |
| Disruptions to menstrual cycle | 50 (46.7%) | 50 (38.8%) | 0.217 | 102 (42.7%) | |
| Dizziness | 41 (38.3%) | 81 (62.8%) | <0.001 | 124 (51.9%) | |
| Increased bleeding | 61 (57.0%) | 95 (73.6%) | 0.007 | 158 (66.1%) | |
| Increased risk of HIV from use | 53 (49.5%) | 108 (83.7%) | <0.001 | 163 (68.2%) | |
| Increased risk of STIs from use | 58 (54.2%) | 111 (86.0%) | <0.001 | 171 (71.5%) | |
| Inconvenient to use | 47 (43.9%) | 77 (59.7%) | 0.016 | 126 (52.7%) | |
| Too expensive | 34 (31.8%) | 87 (67.4%) | <0.001 | 123 (51.5%) | |
| Nausea/vomiting | 50 (46.7%) | 101 (78.3%) | <0.001 | 153 (64.0%) | |
| Unintended pregnancy while using | 50 (46.7%) | 101 (78.3%) | <0.001 | 153 (64.0%) | |
| Weight gain or weight loss | 43 (40.2%) | 75 (58.1%) | 0.006 | 120 (50.2%) | |
| Other | 2 (1.9%) | 21 (16.3%) | - | 23 (9.6%) |
Includes 3 respondents not reporting country of residence and omitted from analysis of country income categories.